ICON Public Limited Company (ICLR)
- Previous Close
300.08 - Open
302.85 - Bid 307.52 x 100
- Ask 308.50 x 100
- Day's Range
300.25 - 310.33 - 52 Week Range
181.92 - 344.77 - Volume
410,713 - Avg. Volume
556,488 - Market Cap (intraday)
25.506B - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
37.39 - EPS (TTM)
8.25 - Earnings Date Jul 24, 2024 - Aug 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
353.69
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
www.iconplc.com41,150
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ICLR
Performance Overview: ICLR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICLR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICLR
Valuation Measures
Market Cap
24.81B
Enterprise Value
28.06B
Trailing P/E
36.42
Forward P/E
20.16
PEG Ratio (5yr expected)
1.15
Price/Sales (ttm)
3.02
Price/Book (mrq)
2.63
Enterprise Value/Revenue
3.46
Enterprise Value/EBITDA
18.44
Financial Highlights
Profitability and Income Statement
Profit Margin
8.30%
Return on Assets (ttm)
4.01%
Return on Equity (ttm)
7.55%
Revenue (ttm)
8.23B
Net Income Avi to Common (ttm)
683.12M
Diluted EPS (ttm)
8.25
Balance Sheet and Cash Flow
Total Cash (mrq)
398.04M
Total Debt/Equity (mrq)
38.64%
Levered Free Cash Flow (ttm)
1.14B
Research Analysis: ICLR
Company Insights: ICLR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ICLR
Analyst Report: ICON Public Limited Company
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
RatingPrice TargetAnalyst Report: ICON Public Limited Company
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
RatingPrice TargetAnalyst Report: ICON Public Limited Company
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
RatingPrice TargetAnalyst Report: ICON Public Limited Company
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
RatingPrice Target